Stockscreener 앱 받기
26.58
1.54%
0.4128
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times
Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan
Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia
Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India
Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia
Immunovant's chief legal officer sells $82,339 in stock - Investing.com India
Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com
Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia
Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
IMVT (Immunovant Inc) has impressive results - US Post News
Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily
Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex
Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha
1.80%
0.42%
자본화:
|
볼륨(24시간):